KSPWFTTL TFA

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

KSPWFTTL TFA  纯度: 99.16%

KSPWFTTL TFA 是一种来自 p15E 跨膜蛋白的免疫显性 Kb 限制性表位。KSPWFTTL TFA 可以恢复肿瘤系对抗 AKR/Gross MuLV 细胞毒性 T 淋巴细胞的敏感性。

KSPWFTTL TFA

KSPWFTTL TFA Chemical Structure

规格 价格 是否有货 数量
5 mg ￥3000 In-stock
10 mg ￥4800 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

KSPWFTTL TFA 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • Anti-Cancer Compound Library
  • Peptide Library

生物活性

KSPWFTTL TFA is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL TFA can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes[1][2].

体外研究
(In Vitro)

KSPWFTTL TFA is derived from the retroviral p15 TM envelope protein. The cytolytic T-lymphocyte (CTL)-insusceptible, variant cl.18-5 clonal line, after pulsed with the KSPWFTTL TFA peptide, becomes susceptible to lysis by antiviral CTL[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

1093.15

Formula

C50H71F3N10O14
Sequence

Lys-Ser-Pro-Trp-Phe-Thr-Thr-Leu
Sequence Shortening

KSPWFTTL
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro: 

H2O : 66.67 mg/mL (60.99 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.9148 mL 4.5739 mL 9.1479 mL
5 mM 0.1830 mL 0.9148 mL 1.8296 mL
10 mM 0.0915 mL 0.4574 mL 0.9148 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. White HD, et, al. An immunodominant Kb-restricted peptide from the p15E transmembrane protein of endogenous ecotropic murine leukemia virus (MuLV) AKR623 that restores susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes. J Virol. 1994 Feb;68(2):897-904.

    [2]. Rich RF, et, al. Antiretroviral cytolytic T-lymphocyte nonresponsiveness: FasL/Fas-mediated inhibition of CD4(+) and CD8(+) antiviral T cells by viral antigen-positive veto cells. J Virol. 1999 May;73(5):3826-34.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务